View Older Stories View More Recent Stories
-
After-hours movers: NVIDIA, Toll Brothers, and more
-
WAVE Life Sciences (WVE) PT Raised to $21 at Raymond James
-
WAVE Life Sciences (WVE) PT Raised to $28 at Leerink Partners
-
WAVE Life Sciences (WVE) PT Raised to $20 at Wedbush
-
Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
-
Wave Life Sciences reports positive obesity trial results
-
WAVE Life Sciences (WVE) Can Show Fat Mass Loss- Cantor Fitzgerald
-
Clear Street Starts WAVE Life Sciences (WVE) at Buy, PT $22
-
WAVE Life Sciences (WVE) PT Lowered to $16 at Jones Trading
-
Raymond James on WAVE Life Sciences (WVE): 'We continue to view WVE’s wholly-owned gene-editing programs as more likely LT value drivers'
-
WAVE Life Sciences (WVE) PT Raised to $26 at Leerink Partners
-
Wave Life Sciences reports positive data from AATD drug trial
-
Canaccord Genuity Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
Canaccord Genuity Starts WAVE Life Sciences (WVE) at Buy, 'making big waves in the RNA space'
-
WAVE Life Sciences (WVE) Misses Q2 EPS by 4c
-
Oppenheimer Starts WAVE Life Sciences (WVE) at Outperform
-
Citi Starts WAVE Life Sciences (WVE) at Buy
-
Cantor Fitzgerald Reiterates Overweight Rating on WAVE Life Sciences (WVE)
-
Cantor Fitzgerald Reiterates Overweight Rating on WAVE Life Sciences (WVE)
-
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
Wave Life Sciences (WVE) Announces Oral Presentation of Preclinical Data Supporting WVE-007
-
WAVE Life Sciences (WVE) 1100 contracts of January 10 calls trade as share price down 2.4%
-
WAVE Life Sciences (WVE) Appoints Christopher Wright as Chief Medical Officer
-
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) Misses Q1 EPS by 4c
-
Cantor Fitzgerald Starts WAVE Life Sciences (WVE) at Overweight
-
Wedbush Starts WAVE Life Sciences (WVE) at Outperform
-
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
Jefferies Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) Announces Positive Data from FORWARD-53 Clinical Trial in DMD
-
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)
-
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
Truist: 'WAVE Life Sciences (WVE) Remains One of Our Favorite Stocks for 2025'
-
WAVE Life Sciences (WVE) PT Raised to $21 at JPMorgan
-
WAVE Life Sciences (WVE) Tops Q4 EPS by 34c
-
Jefferies Starts WAVE Life Sciences (WVE) at Buy
-
WAVE Life Sciences (WVE) announces phase 1 of clinic trial of WVE-007
-
WAVE Life Sciences (WVE) spreader of December 15 and 17.50 calls
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
WAVE Life Sciences (WVE) PT Raised to $36 at Truist Securities
-
Leerink Partners Reiterates Outperform Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) PT Raised to $15 at RBC Capital
-
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
-
WAVE Life Sciences (WVE) PT Raised to $19 at B.Riley
-
JPMorgan Reinstates WAVE Life Sciences (WVE) at Overweight
-
WAVE Life Sciences (WVE) Prices Upsized $200M Share and Warrant Offering
-
Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)

